MGF and PEG-MGF: what the research shows
- By Reed Calder
- Last reviewed Nov 16, 2026
- 38 studies and official documents checked
In short
MGF stands for mechano growth factor. It is the name for a form of IGF-1 that muscle makes after exercise or damage: in people it is the IGF-1Ec splice variant, and its end carries a 24-amino-acid tail called the E peptide. Sellers offer a synthetic copy of that tail, and PEG-MGF, the same peptide joined to a polyethylene glycol chain, as muscle-repair peptides.
What was measured in people is the body’s own MGF messenger RNA, not the peptide. It rose after one bout of leg exercise in 8 young adults but not in 7 older adults (Hameed et al., 2003). The peptide itself was tested in cells and animals. In human muscle-cell cultures it raised progenitor cell numbers or lifespan in two studies, and two drug companies could not repeat the effect (Ates et al., 2007; Kandalla et al., 2011; Fornaro et al., 2014). When mice with damaged muscle were injected with MGF, muscle fibers did not regenerate better, though scarring fell (Liu et al., 2019).
We found no study that gave MGF or PEG-MGF to people. Lab studies found the E peptide made prostate, breast and bone-cancer cells grow, and tumor tissue shows more IGF-1Ec than normal tissue. Doping labs that tested confiscated and black-market products found altered versions, not the human sequence. The FDA has no approval for MGF, lists it in category 3 of its compounding list (nominated without adequate support), and warns about PEG-MGF. The 2026 WADA list names mechano growth factors under S2.3.
EvidenceCellAnimalHumancell and animal studies; people were only measured for their own MGF after exercise
You’ll often read that MGF is the “first responder” that wakes up muscle stem cells, that it builds muscle and speeds recovery, and that PEG-MGF lasts for days instead of minutes. This page covers what MGF is, what was studied in people, cells and animals, the usual claims checked, what the studies used, side effects, where it stands with the FDA and in sport, and what’s still unknown.
Names and forms you’ll see
| Name | What it is | Studied in people? |
|---|---|---|
| MGF, mechano growth factor, IGF-1Ec | A form of IGF-1 made from a different splice of the IGF-1 gene. In people it is IGF-1Ec; the rodent version is IGF-1Eb. The name is used for the gene’s activity, for the tail that would be cut from it, and for the synthetic peptide (Kandalla et al., 2011; Fornaro et al., 2014; Matheny et al., 2010) | Only the body’s own MGF messenger RNA, measured after exercise |
| MGF peptide, MGF E peptide, Ec peptide, MGF-Ct24E | The synthetic 24-amino-acid copy of the tail: YQPPSTNKNTKSQRRKGSTFEERK (FDA GSRS) | We found no study |
| PEG-MGF, pegylated MGF | MGF joined to polyethylene glycol (PEG), a chain meant to make a peptide last longer. We found no published study of PEG-MGF itself; the FDA and a 2026 review say there are no human data (FDA, 2026; Dominikowski et al., 2026) | We found no study |
| MGF R23H | A variant of MGF found in confiscated vials (Cox et al., 2017) | We found no study |
| C-terminal amidated MGF | A form whose last amino acid carries an amide group. Two black-market preparations tested in 2012 were this form (Esposito et al., 2012; FDA GSRS) | We found no study |
| “Full-length MGF” | A longer product offered under that name and analyzed in 2014 (Thevis et al., 2014) | We found no study |
| IGF-1 LR3, IGF-1 DES | Different compounds: changed versions of IGF-1 itself. See IGF-1 LR3 and the IGF-1 DES card | Covered separately |
CAS numbers
A CAS number is a substance’s chemical registry number. Some “research” vials list it in place of a name. A different number usually means a different form, such as a salt, or a different substance. The FDA’s substance registry lists no CAS number for either form; it identifies them with FDA UNII codes.
What MGF is
The IGF-1 gene can be read in more than one way. One product is the IGF-1 that circulates in the blood. Another, made in muscle after exercise or damage, has a different end: in people the IGF-1Ec form has a 49-base insert that shifts the reading frame and adds a unique 24-amino-acid tail (Kandalla et al., 2011). The first report of this form responding to mechanical stress came from Goldspink and colleagues in 1996 (Thevis et al., 2014).
Three different things sit behind the name. One is the gene’s activity, measured as messenger RNA. The second is a peptide the body might cut from that product. The third is the synthetic copy sold in vials, which is what sellers mean by “MGF peptide”.
On the second, a 2010 review said no matching peptide from the Igf1 gene had been isolated from cultured cells, the fluid around them, or animal tissue and body fluids (Matheny et al., 2010). Later work in cancer measured an Ec peptide released by prostate cancer cells and stained IGF-1Ec protein in tumor tissue (Armakolas et al., 2018; Alagaratnam et al., 2020). We didn’t find a study that measured it in human muscle.
Several lab studies say the synthetic peptide acts by a route other than the IGF-1 receptor, the main receptor IGF-1 uses (Mills et al., 2007; Dluzniewska et al., 2005; Armakolas et al., 2010).
A 2006 review by Goldspink, whose lab described the form, said delivering MGF as DNA or as the peptide markedly increased muscle strength (Goldspink, 2006). We found no original study of the peptide with that result in normal animals. The closest is a plasmid, DNA that makes MGF, delivered into the muscles of mice with ALS (Riddoch-Contreras et al., 2009).
What has been studied
We found no study that gave MGF or PEG-MGF to people. PubMed lists 194 records that mention mechano growth factor in the title or abstract (searched November 16, 2026); most are cell, animal or expression studies. The three human studies below measured the body’s own MGF messenger RNA after exercise.
In people: MGF messenger RNA after exercise
| Study | Who | What was done | What it found |
|---|---|---|---|
| Hameed et al., 2003 | 8 young adults aged 25 to 36 and 7 older adults aged 70 to 82 | One-legged knee extensions, 10 sets of 6 at 80% of the most they could lift once; muscle biopsies 2.5 hours later | At rest MGF mRNA was about 100 times lower than IGF-IEa. It rose significantly in the young and not in the older group. IGF-IEa did not change in either |
| McKay et al., 2008 | 8 young adults, average age 20.6 | 300 lengthening contractions of one leg; biopsies at 4, 24, 72 and 120 hours | MGF mRNA peaked at 24 hours; IGF-1Ea and IGF-1Eb mRNA rose about 4 to 6 times by 72 hours. Blood IGF-1 did not change. IGF-1 protein showed up in muscle stem cells at 24 hours |
| Roberts et al., 2010 | 10 men aged 18 to 25 and 10 men aged 60 to 75 | Three workouts in a week, nine sets of ten at 80% of the one-rep maximum; biopsies before and 48, 48 and 24 hours after the three workouts | MGF mRNA rose over the three workouts in the older men only, unlike the 2003 study, though the biopsy times differed. Muscle IGF-1 peptides stayed stable in both groups. The authors say the meaning is unknown |
EvidenceCellAnimalHumanthe body’s own MGF measured; no one was given MGF
In cells: muscle stem cells
| Study | Model | What was used | What it found |
|---|---|---|---|
| Ates et al., 2007 | Human muscle cells from healthy people and people with muscular dystrophy or ALS | The synthetic E peptide | The number of progenitor cells rose in healthy and diseased muscle cells. IGF-1 pushed cells to mature, while the E peptide blocked that step |
| Mills et al., 2007 | Human muscle precursor cells | The 24-amino-acid synthetic peptide | The peptide made the cells move more, and the authors report it did not work through the IGF-1 receptor |
| Kandalla et al., 2011 | Muscle stem cells from newborn, young adult and old adult donors | The 24-amino-acid synthetic peptide | Cells from newborn and young donors lived longer before aging; cells from old donors did not. Muscle fibers grown in the dish were larger in all groups. The authors call it a possible way to fight muscle loss without IGF-1’s cancer effects, which the study did not test |
| Fornaro et al., 2014 | Human and mouse muscle cells, mouse muscle stem cells and heart cells, tested at two drug companies | The synthetic peptide, including a stabilized version, up to 500 ng/ml | No increase in cell growth in any of them, while IGF-1 worked. No effect on turning cells into muscle fibers or on the signal pERK. The authors question whether there is a physiological role for MGF |
EvidenceCellAnimalHumancultured human and mouse cells; two positive studies and one failed repeat
In animals: muscle and nerves
| Study | Model | What was used | What it found |
|---|---|---|---|
| Mills et al., 2007 (transplant) | Mice given human muscle precursor cells | The synthetic peptide, injected into the muscle or given through the blood | More of the human cells took hold in the mouse muscle. This tested cell transplantation, not muscle growth |
| Liu et al., 2019 | Mice with a bruised muscle and the immune cells called macrophages removed | MGF injected into the damaged muscle | Muscle fibers did not regenerate better. Scarring fell, along with inflammation markers and oxidative stress markers |
| Riddoch-Contreras et al., 2009 | Mice with an ALS-type disease | A plasmid that makes MGF, put into the hind leg muscles at symptom onset (DNA, not the peptide) | Hind leg strength improved and more nerve cells survived; IGF-1 DNA gave a similar gain, and MGF saved more nerve cells |
| Dluzniewska et al., 2005 | Gerbils with brief brain ischemia, and brain slice cultures | The synthetic C-terminal peptide | The peptide protected vulnerable neurons in the gerbils; in the slices it was as potent as IGF-1 and lasted longer, and the effect did not need the IGF-1 receptor |
| Quesada et al., 2009 | Rats with a Parkinson-type injury, and nerve cell cultures | The 24-amino-acid peptide, given into the brain or elsewhere in the body | Less loss of dopamine nerve cells and less limb under-use; the effect did not depend on the IGF-1 receptor |
EvidenceCellAnimalHumanmice, rats and gerbils; the muscle-regeneration test in mice was negative
In animals: heart, tendon and bone
| Study | Model | What was used | What it found |
|---|---|---|---|
| Carpenter et al., 2008 | Sheep with a heart attack caused by microspheres | The MGF E domain at 200 nM; mature IGF-I and full-length MGF in one test | The E domain preserved heart function and left 35% less damaged heart muscle than in controls in the second test |
| Peña et al., 2015 | Mice with a coronary artery tied off | Peptide-releasing microrods injected after the heart attack | Fewer deaths, a slower decline in heart function and delayed heart failure |
| Zhang et al., 2016 | Rats with an Achilles tendon injury | MGF-C25E, a synthetic peptide, at 1,000 ng/ml | Better walking score and a stiffer repaired tendon than with saline |
| Deng et al., 2011 | 27 rabbits with a 5 mm gap in the forearm bone | The 24-amino-acid peptide, 28.5 or 57 µg/kg, injected on five consecutive days | More defects healed on X-ray with the high dose than with no growth factor (p < 0.01) |
EvidenceCellAnimalHumansheep, mice, rats and rabbits; none in people
In tumor tissue and cancer cells
| Study | Model | What was used | What it found |
|---|---|---|---|
| Armakolas et al., 2010 | Human prostate tissue and cell lines | Staining and RT-PCR; the synthetic E peptide on cancer cells | MGF was higher in prostate cancer and precancer tissue than in normal tissue, and normal prostate cells did not make it. The E peptide stimulated prostate cancer cell growth without needing the IGF-1 receptor |
| Armakolas et al., 2015 | Human prostate cancer cells; mice; human biopsies | Cells engineered to make the Ec peptide, injected into mice | More cell growth in cells and tumors, and a higher rate of spread in mice. In biopsies, IGF-1Ec expression rose with tumor stage |
| Christopoulos et al., 2017 | Human breast cancer cell lines | The synthetic Ec peptide | Stimulated growth and movement of MCF-7 cells (estrogen-responsive) but not MDA-MB-231 cells |
| Shang et al., 2015 | Human osteosarcoma cell lines | The synthetic E peptide | MGF was made by the malignant lines, and the peptide promoted their growth, movement and invasion |
| Alagaratnam et al., 2020 | Tissue from 16 patients with colorectal cancer, 11 with polyps and normal colon | Staining for IGF-1Ec | More IGF-1Ec in cancer and polyps than in normal colon, and more in polyps with high-grade dysplasia |
| He et al., 2018 | Melanoma cells (the GLL19 line) | The E peptide at 10, 20 and 30 ng/ml | Fewer cells invaded, with stress in the cell’s protein-folding compartment and more cell death: the opposite direction from the other cancer studies |
EvidenceCellAnimalHumantissue samples, cell lines and mice; no one was given MGF
In products tested by doping labs
| Study | What was tested | What it found |
|---|---|---|
| Esposito et al., 2012 | Two black-market products sold as MGF | Both were C-terminal amidated analogues of human MGF, not the human form |
| Cox et al., 2017 | Confiscated vials | Contained a variant, MGF R23H (and BPC 157). In plasma tests in a dish the variant was stable |
| Thevis et al., 2014 | A product sold as “full-length MGF” through illicit channels | The lab characterized it and added it to its doping tests. MGF has been on WADA’s list since 2005 |
| Dominikowski et al., 2026 | A 2026 review of PEG-MGF and other performance peptides | No peer-reviewed human study of PEG-MGF. Pegylation is meant to extend stability, and no half-life has been reported |
EvidenceCellAnimalHumanlaboratory analyses of products; not studies of effects in people
The usual claims, checked
| Claim | Verdict | What the studies found |
|---|---|---|
| Exercise makes muscle produce MGF | Mixed | The body’s MGF messenger RNA rose after exercise in young adults in two studies, and not in older adults in one. In another study it rose only in older men. No study found the peptide in human muscle (Hameed et al., 2003; McKay et al., 2008; Roberts et al., 2010; Matheny et al., 2010) |
| The MGF peptide activates muscle stem cells | Mixed | The peptide raised progenitor cell numbers in two human cell studies, but not in cells from old donors in one. Two drug companies could not reproduce it (Ates et al., 2007; Kandalla et al., 2011; Fornaro et al., 2014) |
| MGF builds muscle | Untested | We found no study in people and no animal study of the injected peptide raising muscle size or strength. In mice with a bruised muscle, an MGF injection did not improve fiber regeneration (Liu et al., 2019) |
| MGF speeds recovery from injury | Untested | We found no study in people. In animals it helped tendon and bone healing in single studies and reduced scarring in mouse muscle (Zhang et al., 2016; Deng et al., 2011; Liu et al., 2019) |
| PEG-MGF lasts for days, so it works better | Untested | We found no study of PEG-MGF. A 2026 review reports no human study and no half-life (Dominikowski et al., 2026) |
| MGF lasts only minutes in the body | Untested | We found no study that measured how long MGF lasts in animals or people. In a plasma test in a dish, the R23H variant was stable (Cox et al., 2017) |
| The MGF in a vial is the human peptide | Contradicted | Doping labs found C-terminal amidated analogues, an R23H variant and a product sold as full-length MGF in black-market and confiscated samples (Esposito et al., 2012; Cox et al., 2017; Thevis et al., 2014) |
| It is safe because the body makes it | Untested | We found no safety study in people. The body’s MGF activity is higher in several tumors, and the E peptide stimulated some cancer cells to grow (Armakolas et al., 2010; Alagaratnam et al., 2020; Christopoulos et al., 2017) |
| It has no cancer risk, unlike IGF-1 | Mixed | Mixed. The cell paper that raised this says it was not tested. The E peptide stimulated prostate, breast and bone-cancer cells, and reduced the invasion of melanoma cells (Kandalla et al., 2011; Armakolas et al., 2015; Shang et al., 2015; He et al., 2018) |
| It protects the heart and brain | Untested | Animal studies only: sheep and mouse heart attacks, gerbil brain ischemia and a rat Parkinson model. None in people (Carpenter et al., 2008; Peña et al., 2015; Dluzniewska et al., 2005; Quesada et al., 2009) |
| MGF has been tested in people | Contradicted | We found no study that gave MGF or PEG-MGF to people. The human studies measured the body’s own MGF messenger RNA (Hameed et al., 2003; Dominikowski et al., 2026) |
| MGF is an FDA-approved drug | Contradicted | No. We found no Drugs@FDA application. One bulk-ingredient listing exists, and the FDA put MGF in category 3 of its compounding list, nominated without adequate support (openFDA; openFDA NDC; FDA document) |
| MGF is banned in sport | Supported | Yes. The 2026 WADA list, section S2.3, names mechano growth factors, prohibited at all times (WADA, 2026) |
Verdict key. Supported: controlled data in people, or the official record, back it. Mixed: studies disagree, or the support is small or limited to one use. Untested: we found no study in people. Contradicted: the studies or record we found show no effect or the opposite.
What the studies used
| Study | What was tested | Amount and route |
|---|---|---|
| Fornaro et al., 2014 | Muscle cells in a dish | The peptide at up to 500 ng/ml, including a stabilized form |
| Deng et al., 2011 | Bone healing in rabbits | 28.5 or 57 µg/kg, injected on five consecutive days |
| Zhang et al., 2016 | Tendon healing in rats | MGF-C25E at 1,000 ng/ml |
| Carpenter et al., 2008 | Heart attack in sheep | The MGF E domain at 200 nM |
Every amount above is a laboratory or animal amount. We found no human dose, and the people-studies above gave no MGF. Nothing here is a dosing recommendation, and we don’t repeat vial sizes or schedules from seller pages.
Side effects and safety
- In people. We found no study that gave MGF or PEG-MGF to people, so there are no human side-effect data. A missing report of harm isn’t evidence of safety.
- Growth in cancer cells. MGF was more abundant in prostate and colorectal tumor tissue, and the E peptide stimulated prostate, breast and bone-cancer cells to grow; in mice, prostate cells engineered to make it spread more. In one melanoma study the peptide reduced invasion. These are cell and mouse studies, not human risk estimates (Armakolas et al., 2010; Armakolas et al., 2015; Christopoulos et al., 2017; Shang et al., 2015; Alagaratnam et al., 2020; He et al., 2018).
- PEG-MGF and the FDA. The FDA says compounded PEG-MGF may carry a significant risk of immunogenicity for certain routes, that peptide-related impurities and API characterization are complex, and that it has found no data on people exposed to it by any route (FDA, 2026).
- Product identity. The products doping labs tested were altered versions, so what a vial contains may not match what the studies used (Esposito et al., 2012; Cox et al., 2017; Thevis et al., 2014).
- What the 2011 cell study claims. It calls the peptide a way to fight age-related muscle loss “without the oncogenic side effects observed for IGF1”. It did not test that (Kandalla et al., 2011).
- Not known. Whether it is safe in people at any amount, long-term safety, pregnancy, interactions, injection-site effects and how long it lasts. Side effects people report online aren’t covered here; they come from users, not studies.
Legal and approval status
- Not approved. We found no Drugs@FDA application for MGF (openFDA). The FDA’s drug listing directory has one “bulk ingredient” listing for an MGF acetate powder, in 1 g containers, listed since March 30, 2021; its active-ingredient field names mecasermin, which is IGF-1 itself. A bulk-ingredient listing is not an approval (openFDA NDC).
- Compounding. The FDA lists mechano growth factor (MGF) in category 3 of its 503A bulk drug substance list, “nominated without adequate support”, updated May 14, 2026. Its page of bulk substances that may present significant safety risks, current as of April 22, 2026, names PEG-MGF (FDA document; FDA page). We did not research whether pharmacies may lawfully compound it.
- Not in the HHS policy. The October 2026 temporary policy covers six other peptides, not MGF (Reuters, 2026).
- Other countries. We did not check how other countries regulate it.
- Sport. The World Anti-Doping Agency’s 2026 list, section S2.3, names mechano growth factors (MGFs) and IGF-1 and its analogues, prohibited at all times (WADA, 2026). A 2014 doping-lab paper says MGF has been banned since 2005 (Thevis et al., 2014).
What to look for if you research it
We don’t name or link sellers. These checks come from the studies and from the FDA:
- “Natural, made by your muscle.” What muscle makes is a messenger RNA that was measured in biopsies. We found no study that measured the peptide in human muscle. A synthetic copy is a different thing.
- “Human studies.” The human studies measured the body’s own MGF after exercise. None gave anyone MGF or PEG-MGF.
- “Builds muscle.” No study shows it in people. The one mouse test of an injection in damaged muscle did not improve fiber regeneration.
- “PEG-MGF lasts days.” We found no study of PEG-MGF, and no half-life has been reported.
- Identity. The human peptide has 24 amino acids. Doping labs found amidated and R23H versions and a “full-length” product. Ask for a report that checks the sequence and mass for the batch.
- Cancer. It is a growth signal in several cancer cell lines. Ask what a claim of no cancer risk rests on.
- Competition. The 2026 WADA list names it.
Our guide to what to look for explains what each test on a lab report proves and which routes are legal; how to read a peptide study explains how to judge the studies sellers cite.
Trials under way
We found no MGF or PEG-MGF trial that is recruiting or active, so there is nothing to list on our recruiting or in-progress pages. ClinicalTrials.gov searches on November 16, 2026 for mechano growth factor, MGF peptide, PEG-MGF and IGF-1Ec found no record that gives MGF to anyone (search). One record names IGF-1Ec: NCT07151807, an observational study of blood IGF-1Ec as a tumor marker in about 100 patients with solid tumors, active and not recruiting. Observational studies stay off our trials lists. A registry search isn’t proof that no unregistered study exists.
What’s still unknown
- Whether any form of MGF raises muscle size or strength in people; we found no study that gave it to anyone.
- Whether the body makes the E peptide in muscle at all; the measurements in muscle are of messenger RNA.
- What PEG-MGF is, how long it lasts and whether it does anything; we found no published study of it.
- How long unmodified MGF lasts in the body; we found no measurement.
- Whether it raises cancer risk in people, given the findings in tumor tissue and cancer cell lines.
- What is in MGF sold now; the identity studies we found tested confiscated and black-market samples from 2012 to 2017.
Retracted and flagged studies
A retracted study has been pulled by its journal, usually for serious errors or misconduct, and its results shouldn’t be relied on. A withdrawn paper was pulled, often before final publication. An expression of concern means the journal has flagged a problem it is still looking into.
We check every study this page cites against PubMed and the Retraction Watch database, and search both for flagged studies that mention MGF. We recheck every month. Last checked Nov 16, 2026.
Flagged studies that mention MGF
| Study | What it was about | Status |
|---|---|---|
| Xu et al., 2019 | Mechano growth factor attenuates mechanical overload-induced nucleus pulposus cell apoptosis through inhibiting the p38 MAPK pathway. | Retracted (2024) · notice |
Studies this page relies on
| Study | Published in | Status |
|---|---|---|
| Hameed et al., 2003 | J Physiol | No retraction or concern |
| Dluzniewska et al., 2005 | FASEB J | No retraction or concern |
| Goldspink, 2006 | Int J Biochem Cell Biol | No retraction or concern |
| Mills et al., 2007 | Exp Cell Res | No retraction or concern |
| Ates et al., 2007 | FEBS Lett | No retraction or concern |
| Carpenter et al., 2008 | Heart Lung Circ | No retraction or concern |
| Mills et al., 2007 | Am J Transplant | No retraction or concern |
| McKay et al., 2008 | J Physiol | No retraction or concern |
| Riddoch-Contreras et al., 2009 | Exp Neurol | No retraction or concern |
| Quesada et al., 2009 | Exp Neurol | No retraction or concern |
| Matheny et al., 2010 | Endocrinology | No retraction or concern |
| Armakolas et al., 2010 | Prostate | No retraction or concern |
| Roberts et al., 2010 | Eur J Appl Physiol | No retraction or concern |
| Deng et al., 2011 | Int Orthop | No retraction or concern |
| Kandalla et al., 2011 | Mech Ageing Dev | No retraction or concern |
| Esposito et al., 2012 | Rapid Commun Mass Spectrom | No retraction or concern |
| Fornaro et al., 2014 | Am J Physiol Endocrinol Metab | No retraction or concern |
| Thevis et al., 2014 | Growth Horm IGF Res | No retraction or concern |
| Armakolas et al., 2015 | Mol Med | No retraction or concern |
| Peña et al., 2015 | Biomaterials | No retraction or concern |
| Shang et al., 2015 | Oncol Lett | No retraction or concern |
| Zhang et al., 2016 | Biotechnol Lett | No retraction or concern |
| Cox et al., 2017 | Drug Test Anal | No retraction or concern |
| Christopoulos et al., 2017 | Anticancer Res | No retraction or concern |
| He et al., 2018 | Biotechnol Lett | No retraction or concern |
| Armakolas et al., 2018 | Mol Med | No retraction or concern |
| Liu et al., 2019 | Front Physiol | No retraction or concern |
| Alagaratnam et al., 2020 | J Cancer Res Clin Oncol | No retraction or concern |
| Dominikowski et al., 2026 | Front Endocrinol (Lausanne) | No retraction or concern |
Bring your questions to other researchers
Our forum opens once 100 researchers join the waitlist. Members post studies, ask what they actually found, and answer with sources.
Questions
What is MGF?
MGF is mechano growth factor, a form of IGF-1 made from a different splice of the IGF-1 gene (IGF-1Ec in people). Its end carries a 24-amino-acid tail called the E peptide, and sellers offer a synthetic copy of it (Kandalla et al., 2011; FDA GSRS).
What is MGF peptide used for?
Sellers market it for muscle repair, recovery and growth. We found no study that gave it to people, and the human studies measured only the body’s own MGF messenger RNA after exercise (Hameed et al., 2003).
Does MGF build muscle?
We found no study in people, and no animal study of the injected peptide raising muscle size or strength. In mice with a bruised muscle, an MGF injection did not improve fiber regeneration but reduced scarring (Liu et al., 2019).
What is PEG-MGF?
PEG-MGF is MGF joined to polyethylene glycol, a chain meant to extend how long a peptide lasts. We found no published study of PEG-MGF, and a 2026 review reports no human study and no half-life (Dominikowski et al., 2026).
What is the difference between MGF and PEG-MGF?
PEG-MGF carries a polyethylene glycol chain. Sellers say it lasts days instead of minutes, but we found no study that measured how long either lasts (Dominikowski et al., 2026).
What is the difference between MGF and IGF-1?
IGF-1 is the growth factor that circulates in the blood. MGF is a form made from a different splice of the same gene, with a different end. Lab studies say the MGF peptide can act without the IGF-1 receptor (Mills et al., 2007; Matheny et al., 2010).
Does exercise raise MGF?
The body’s MGF messenger RNA rose after leg exercise in young adults in two studies, and in older men in another. Whether the peptide is made in human muscle hasn’t been shown (Hameed et al., 2003; McKay et al., 2008; Roberts et al., 2010; Matheny et al., 2010).
What are the side effects of MGF?
We found no human side-effect data. Lab and animal findings include growth of prostate, breast and bone-cancer cells, and the FDA warns of immunogenicity and impurities with PEG-MGF (Armakolas et al., 2010; Christopoulos et al., 2017; Shang et al., 2015; FDA, 2026).
Does MGF cause cancer?
Unknown in people. MGF is more abundant in prostate and colorectal tumor tissue, the E peptide stimulated several cancer cell lines, and in one melanoma study it reduced invasion (Armakolas et al., 2010; Alagaratnam et al., 2020; He et al., 2018).
What dose of MGF did the studies use?
Only laboratory and animal amounts: for example 28.5 or 57 µg/kg on five consecutive days in rabbits, and up to 500 ng/ml on cells. There is no human dose. See what the studies used. It is not a dosing recommendation (Deng et al., 2011; Fornaro et al., 2014).
How long does MGF last in the body?
We found no measurement in animals or people. Sellers say minutes for MGF and days for PEG-MGF; in a plasma test in a dish, the R23H variant was stable (Cox et al., 2017).
Is the MGF peptide the same as natural MGF?
Not necessarily. Doping labs found C-terminal amidated analogues, an R23H variant and a product sold as full-length MGF (Esposito et al., 2012; Cox et al., 2017; Thevis et al., 2014).
Is MGF FDA-approved?
No. We found no Drugs@FDA application. The FDA lists MGF in category 3 of its compounding list, nominated without adequate support (openFDA; FDA document).
Is MGF banned in sport?
Yes. The 2026 WADA list, section S2.3, names mechano growth factors, prohibited at all times (WADA, 2026).
What is the difference between MGF and IGF-1 LR3?
They are different compounds. IGF-1 LR3 is a changed version of IGF-1 itself; MGF is a form made from a different splice of the gene. See what the research shows on IGF-1 LR3.
Are there MGF clinical trials recruiting?
We found none. One registry record names IGF-1Ec, an observational blood-marker study in cancer (NCT07151807).
Sources
- Hameed M, et al. Expression of IGF-I splice variants in young and old human skeletal muscle after high resistance exercise. J Physiol. 2003;547(Pt 1):247-54. PubMed 12562960
- McKay BR, et al. Co-expression of IGF-1 family members with myogenic regulatory factors following acute damaging muscle-lengthening contractions in humans. J Physiol. 2008;586(22):5549-60. PubMed 18818249
- Roberts MD, et al. IGF-1 splice variant and IGF-1 peptide expression patterns in young and old human skeletal muscle prior to and following sequential exercise bouts. Eur J Appl Physiol. 2010;110(5):961-9. PubMed 20668872
- Matheny RW, et al. Minireview: Mechano-growth factor: a putative product of IGF-I gene expression involved in tissue repair and regeneration. Endocrinology. 2010;151(3):865-75. PubMed 20130113
- Armakolas A, et al. IL-6 is associated to IGF-1Ec upregulation and Ec peptide secretion, from prostate tumors. Mol Med. 2018;24(1):6. PubMed 30134795
- Ates K, et al. The IGF-I splice variant MGF increases progenitor cells in ALS, dystrophic, and normal muscle. FEBS Lett. 2007;581(14):2727-32. PubMed 17531227
- Mills P, et al. A new pro-migratory activity on human myogenic precursor cells for a synthetic peptide within the E domain of the mechano growth factor. Exp Cell Res. 2007;313(3):527-37. PubMed 17156777
- Mills P, et al. A synthetic mechano growth factor E Peptide enhances myogenic precursor cell transplantation success. Am J Transplant. 2007;7(10):2247-59. PubMed 17845560
- Kandalla PK, et al. Mechano Growth Factor E peptide (MGF-E), derived from an isoform of IGF-1, activates human muscle progenitor cells and induces an increase in their fusion potential at different ages. Mech Ageing Dev. 2011;132(4):154-62. PubMed 21354439
- Fornaro M, et al. Mechano-growth factor peptide, the COOH terminus of unprocessed insulin-like growth factor 1, has no apparent effect on myoblasts or primary muscle stem cells. Am J Physiol Endocrinol Metab. 2014;306(2):E150-6. PubMed 24253050
- Liu X, et al. Impaired Skeletal Muscle Regeneration Induced by Macrophage Depletion Could Be Partly Ameliorated by MGF Injection. Front Physiol. 2019;10:601. PubMed 31164836
- Riddoch-Contreras J, et al. Mechano-growth factor, an IGF-I splice variant, rescues motoneurons and improves muscle function in SOD1(G93A) mice. Exp Neurol. 2009;215(2):281-9. PubMed 19038252
- Carpenter V, et al. Mechano-growth factor reduces loss of cardiac function in acute myocardial infarction. Heart Lung Circ. 2008;17(1):33-9. PubMed 17581790
- Peña JR, et al. Localized delivery of mechano-growth factor E-domain peptide via polymeric microstructures improves cardiac function following myocardial infarction. Biomaterials. 2015;46:26-34. PubMed 25678113
- Dluzniewska J, et al. A strong neuroprotective effect of the autonomous C-terminal peptide of IGF-1 Ec (MGF) in brain ischemia. FASEB J. 2005;19(13):1896-8. PubMed 16144956
- Quesada A, et al. C-terminal mechano growth factor protects dopamine neurons: a novel peptide that induces heme oxygenase-1. Exp Neurol. 2009;220(2):255-66. PubMed 19735655
- Zhang B, et al. Mechano-growth factor E peptide promotes healing of rat injured tendon. Biotechnol Lett. 2016;38(10):1817-25. PubMed 27334712
- Deng M, et al. Mechano growth factor E peptide promotes osteoblasts proliferation and bone-defect healing in rabbits. Int Orthop. 2011;35(7):1099-106. PubMed 21057789
- Armakolas A, et al. Preferential expression of IGF-1Ec (MGF) transcript in cancerous tissues of human prostate: evidence for a novel and autonomous growth factor activity of MGF E peptide in human prostate cancer cells. Prostate. 2010;70(11):1233-42. PubMed 20564425
- Armakolas A, et al. Oncogenic Role of the Ec Peptide of the IGF-1Ec Isoform in Prostate Cancer. Mol Med. 2015;21(1):167-79. PubMed 25569803
- Christopoulos PF, et al. The COOH-terminus of the IGF-1Ec Isoform Enhances the Proliferation and Migration of Human MCF-7 Breast Cancer Cells. Anticancer Res. 2017;37(6):2899-2912. PubMed 28551627
- Shang J, et al. The role of mechano-growth factor E peptide in the regulation of osteosarcoma. Oncol Lett. 2015;10(2):697-704. PubMed 26622556
- Alagaratnam S, et al. Increased expression of IGF-1Ec with increasing colonic polyp dysplasia and colorectal cancer. J Cancer Res Clin Oncol. 2020;146(11):2861-2870. PubMed 32772171
- He J, et al. Mechano growth factor E peptide inhibits invasion of melanoma cells and up-regulates CHOP expression via endoplasmic reticulum stress. Biotechnol Lett. 2018;40(1):205-213. PubMed 28986701
- Esposito S, et al. Characterization and identification of a C-terminal amidated mechano growth factor (MGF) analogue in black market products. Rapid Commun Mass Spectrom. 2012;26(6):686-92. PubMed 22328223
- Cox HD, et al. Detection and in vitro metabolism of the confiscated peptides BPC 157 and MGF R23H. Drug Test Anal. 2017;9(10):1490-1498. PubMed 28035768
- Thevis M, et al. Mass spectrometric characterization of a biotechnologically produced full-length mechano growth factor (MGF) relevant for doping controls. Growth Horm IGF Res. 2014;24(6):276-80. PubMed 25466910
- Dominikowski A, et al. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. Front Endocrinol (Lausanne). 2026;17:1822475. PubMed 42395176
- Goldspink G. Impairment of IGF-I gene splicing and MGF expression associated with muscle wasting. Int J Biochem Cell Biol. 2006;38(3):481-9. PubMed 16463438
- ClinicalTrials.gov. Searches for mechano growth factor, MGF peptide, PEG-MGF and IGF-1Ec, November 16, 2026: no record that gives MGF to anyone; one observational record, NCT07151807, names IGF-1Ec. Search
- World Anti-Doping Agency. 2026 Prohibited List, section S2.3 (growth factors, including mechano growth factors). WADA document
- U.S. Food and Drug Administration. openFDA Drugs@FDA: searches for mechano growth factor and MGF found no application, November 16, 2026. openFDA
- U.S. Food and Drug Administration. openFDA drug listings (NDC): one bulk-ingredient listing for an MGF acetate powder, November 16, 2026. openFDA NDC
- U.S. Food and Drug Administration. Safety risks associated with certain bulk drug substances nominated for use in compounding (content current as of April 22, 2026; PEG-MGF named). FDA page
- U.S. Food and Drug Administration. Bulk drug substances nominated for use in compounding under section 503A: categories, updated May 14, 2026 (mechano growth factor in category 3). FDA document
- Reuters. U.S. health department to allow temporary sale of some unapproved peptides. October 28, 2026. Article
- U.S. Food and Drug Administration. Global Substance Registration System: Mechano growth factor (UNII Q86M4KXC2P). GSRS
- U.S. Food and Drug Administration. Global Substance Registration System: Mechano growth factor amide (UNII Y65LH7J9BL). GSRS
Last reviewed Nov 16, 2026. Approval and compounding status change often; we recheck this page when they do. Nothing here is medical advice; see our medical disclaimer. Found a mistake? Email editors@peptideresearchstudy.com.